Prepping for pertuzumab

Doctors say the latest Phase III data for pertuzumab should cement its place as standard of care for first-line metastatic breast cancer, but they are even more excited about upcoming data for the mAb in adjuvant patients, which could establish its ability to prevent progression in the first place.

This month, Roche and its Genentech Inc. unit presented detailed results from the double-blind, international Phase III CLEOPATRA trial of pertuzumab in first-line metastatic breast cancer. The companies had reported in July that pertuzumab met the primary endpoint of progression-free survival (PFS)...